Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has received an average rating of “Hold” from the twenty-two research firms that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $47.31.
A number of analysts have recently commented on PCRX shares. Mizuho reissued a “buy” rating and set a $53.00 target price on shares of Pacira Pharmaceuticals in a research note on Monday, September 25th. Needham & Company LLC reissued a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Tuesday, September 26th. Goldman Sachs Group started coverage on shares of Pacira Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $41.00 target price for the company. Canaccord Genuity reissued a “buy” rating and set a $44.00 target price (down previously from $48.00) on shares of Pacira Pharmaceuticals in a research note on Sunday, October 1st. Finally, Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 target price for the company in a research note on Tuesday, October 3rd.
In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 10,000 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the transaction, the chief accounting officer now directly owns 23,455 shares in the company, valued at approximately $938,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark A. Kronenfeld bought 1,000 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was purchased at an average price of $41.60 per share, for a total transaction of $41,600.00. Following the completion of the acquisition, the director now directly owns 6,795 shares in the company, valued at $282,672. The disclosure for this purchase can be found here. Insiders sold a total of 98,960 shares of company stock worth $3,868,341 over the last quarter. 6.60% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the business. Bouchey Financial Group Ltd acquired a new position in Pacira Pharmaceuticals in the 4th quarter valued at about $205,000. Public Employees Retirement System of Ohio boosted its holdings in Pacira Pharmaceuticals by 7.5% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 40,174 shares of the company’s stock valued at $1,509,000 after purchasing an additional 2,808 shares during the last quarter. Granahan Investment Management Inc. MA boosted its holdings in Pacira Pharmaceuticals by 19.6% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 168,464 shares of the company’s stock valued at $6,326,000 after purchasing an additional 27,609 shares during the last quarter. Highbridge Capital Management LLC lifted its holdings in shares of Pacira Pharmaceuticals by 4.4% in the 3rd quarter. Highbridge Capital Management LLC now owns 202,700 shares of the company’s stock worth $7,611,000 after acquiring an additional 8,618 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. acquired a new position in shares of Pacira Pharmaceuticals in the 3rd quarter worth approximately $2,267,000.
Shares of Pacira Pharmaceuticals (NASDAQ PCRX) opened at $39.10 on Friday. The company has a market cap of $1,590.00, a PE ratio of -29.85 and a beta of 2.20. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99. Pacira Pharmaceuticals has a one year low of $29.81 and a one year high of $58.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.15. The business had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.20 earnings per share. research analysts forecast that Pacira Pharmaceuticals will post -0.85 EPS for the current fiscal year.
WARNING: “Pacira Pharmaceuticals, Inc. (PCRX) Receives Average Rating of “Hold” from Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/19/pacira-pharmaceuticals-inc-pcrx-receives-average-rating-of-hold-from-brokerages-2.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.